Robert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.
Robert Rintoul, BSc, MB ChB, MRCP, PhD, FRCP
Advertisement
Articles by Robert Rintoul, BSc, MB ChB, MRCP, PhD, FRCP
Advertisement
Latest Updated Articles
Dr. Rintoul on the Importance of MRD Assessment in NSCLCPublished: June 22nd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5